Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who received Dapagliflozin together with standard anti-cancer treatment, androgen deprivation therapy (ADT) combined with novel hormonal agent (NHA), had better tumor control than those having ADT and NHA.

NCT Number	NCT07310433
Lead Sponsor	Yung NA Collaborators: Ruijin Hospital, Huashan Hospital
Conditions	Prostate Cancer, Metastatic Prostate Cancer
Enrollment	60 participants
Start Date	2026-06-01
Primary Completion	2029-10-30 (estimated)
Study Completion	2030-10-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-30